Latest UK asthma guidance provides minimal change to exacerbation management
The latest guideline update from NICE/BTS/SIGN on the management of Asthma has been released. While there are some significant changes in the approach to chronic asthma diagnosis and management, little has been changed in relation to the management of exacerbations of Asthma. The document continues to regularly link to the 2024 guidance, SIGN 158.[49]
Updates of note relating to asthma exacerbations:
Regular FeNO testing may lead to a reduction in exacerbations.
In people who present with an exacerbation of undiagnosed asthma, it is recommended to start MART (Maintenance And Reliever Therapy) alongside any treatment for the acute symptoms. This is a combination of Inhaled Corticosteroid with Formoterol). This may be stepped down to ‘as needed’ post discharge.[50]
Summary
Definition
History and exam
Key diagnostic factors
- shortness of breath
- cough
- wheeze
- risk factors
- progressive chest tightness
- progressive decrease in lung function
- tachypnoea
- tachycardia
- silent chest
- accessory muscle use
- sleep disturbance
Other diagnostic factors
- exercise limitation
- collapse
- altered consciousness
- skin symptoms
- cyanosis
- arrhythmia
- hypotension
- exhaustion
- stridor
Risk factors
- viral infection
- uncontrolled asthma symptoms
- high use of short-acting beta-2 agonists
- inadequate use of inhaled corticosteroids
- incorrect inhaler technique
- low forced expiratory volume in 1 second (FEV1)
- high bronchodilator reversibility
- current smoker (including e-cigarettes/vapes) or exposure to second-hand cigarette smoke
- exposure to allergens (including history of seasonal allergic rhinitis)
- air pollution
- poor indoor air quality
- obesity
- chronic rhinosinusitis
- gastro-oesophageal reflux disease
- confirmed food allergy
- history of asthma
- history of hospitalisation for asthma exacerbations
- one or more severe exacerbations in the last 12 months
- use of oral corticosteroids
- poor adherence to asthma treatment
- pregnancy
- psychological or socioeconomic problems
- blood eosinophils
- elevated fractional exhaled nitric oxide (FeNO)
- respiratory bacterial infection
Diagnostic investigations
1st investigations to order
- arterial blood gas (in hospital)
- peak flow (in the community and in hospital)
- pulse oximetry (in the community and in hospital)
- chest x-ray (in hospital)
Investigations to consider
- full blood count (in hospital)
- urea and electrolytes (in hospital)
- C-reactive protein (in hospital)
- theophylline levels (in hospital)
- ECG (in hospital)
Treatment algorithm
Contributors
Expert advisers
Jonathan Bennett, MD
Honorary Professor of Respiratory Sciences
University of Leicester
Respiratory Consultant
Glenfield Hospital
Leicester
UK
Biography
JB is deputy medical director of the Royal College of Physicians (RCP) Invited Service Reviews, and speaker at national society meetings including the British Thoracic Society, the Primary Care Respiratory Society, and the Society for Cardiothoracic Surgery.
Disclosures
JB is deputy medical director of RCP Invited Service Reviews.
Acknowledgements
BMJ Best Practice would like to gratefully acknowledge the previous expert contributors, whose work has been retained in parts of the content:
Sourav Majumdar, MD
Clinical Assistant Professor (Affiliated)
Division of Pulmonary, Allergy and Critical Care Medicine
Department of Medicine
Stanford University School of Medicine
Stanford
Lauren Eggert, MD
Fellow
Division of Pulmonary, Allergy and Critical Care Medicine
Department of Medicine
Stanford University School of Medicine
Stanford
Disclosures
SM and LE declare that they have no competing interests.
Peer reviewers
Pujan H Patel, MD
Consultant in Respiratory Medicine
Royal Brompton Hospital
London
UK
Disclosures
PP has received speaker fees for educational lecture events from GlaxoSmithKline.
Editors
Emma Quigley
Section Editor, BMJ Best Practice
Disclosures
EQ declares that she has no competing interests.
Tannaz Aliabadi-Oglesby
Lead Section Editor, BMJ Best Practice
Disclosures
TAO declares that she has no competing interests.
Julie Costello
Comorbidities Editor, BMJ Best Practice
Disclosures
JC declares that she has no competing interests.
Adam Mitchell
Drug Editor, BMJ Best Practice
Disclosures
AM declares that he has no competing interests.
Use of this content is subject to our disclaimer